And what we've done so far is consistent with what we've disclosed for the site, the sites, both Iovance and our CMO, in terms of the capacities that we're projecting for the market.

Source: https://seekingalpha.com/article/4625739-iovance-biotherapeutics-inc-iova-q2-2023-earnings-call-transcript?source=feed_all_articles

Endurant Capital Management LP acquired a new position in Iovance Biotherapeutics during the fourth quarter valued at approximately $451,000.

Source: https://www.americanbankingnews.com/2023/08/24/artisan-partners-limited-partnership-has-21-81-million-position-in-iovance-biotherapeutics-inc-nasdaqiova.html

Finally, US Bancorp DE raised its position in Iovance Biotherapeutics by 72.7% in the 1st quarter.

Source: https://www.americanbankingnews.com/2023/11/07/arizona-state-retirement-system-raises-stock-position-in-iovance-biotherapeutics-inc-nasdaqiova.html

However, Iovance reported a net loss of $107.4 million, equivalent to $0.50 per share, in Q1 2023, compared to a loss of $91.6 million, or $0.58 per share, in Q1 2022.

Source: https://seekingalpha.com/article/4616359-iovance-biotherapeutics-evaluating-recent-developments-fda-feedback?source=feed_all_articles

Iovance Biotherapeutics shares last traded at $8.63, with a volume of 1,095,573 shares traded.

Source: https://www.etfdailynews.com/2023/12/26/iovance-biotherapeutics-nasdaqiova-shares-gap-up-to-8-34/